Navigation Links
Third artificial heart patient introduced

The third man to receive an experimental artificial heart made his first public appearance, three-and-a-half months after getting the device.// Bobby Harrison appeared at a news conference with members of his surgical team from the Texas Heart Institute, where he underwent surgery on September 26, 2001.

The AbioCor heart is a battery-powered plastic-and-titanium device that's completely implanted into the patient. Its internal battery is continually recharged by an external battery pack a patient wears at his waist. Harrison is one of six patients who have received the AbioCor as part of a clinical trial of the device. In order to be eligible, patients must have severe heart failure with an 80-percent chance of dying within a month, and have no other treatment options.

The first man to get the implant, 59-year-old Robert Tools, survived almost five months with it. He died November 30 from severe abdominal bleeding and organ failure, which doctors said was not related to the performance of the artificial heart. The fourth person to get the implant, an unidentified 74-year-old man, died after 56 days with the device. The sixth patient died in surgery to implant the heart. Four additional implants have been approved by the Food and Drug Administration but have not been carried out yet.
'"/>




Page: 1

Related medicine news :

1. Third generation Small pox vaccine from Cell-culture
2. Surgery Offers Better Treatment For Third Degree Piles
3. One Third Of All Cancers Preventable!
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Kleins Third Way Has Tough Opposition
6. Ignorance about AIDS rampart in Third of College Students: Chinese survey
7. Jalgaon: Third Phase Of Culling Operations Begin
8. Pramod Mahajan Undergoes Third Surgery
9. Third Arm Removed Successfully
10. Erection Drug Was Not Useful to Two-Thirds of Its Users
11. Babies Could Be exposed to Third Hand Smoke If Parents Are Smokers
Post Your Comments:
(Date:8/29/2008)...l., Aug. 29 /PRNewswire-FirstCall/ -- Landauer, In...irectors declared a regular,quarterly cash dividen...cal,2008. The dividend will be paid on October 3, ...008., About Landauer, Landauer is the leading pr...ional and environmental radiation exposure. For mo...
(Date:8/29/2008)... AMD presents Telemedicine Encounter Mana... State delegations as a possible solution to natio... N.Chelmsford, MA (PRWEB) August 29, 2008 -- If ...by the speakers at the Democratic National Convent...esolve our national health care issues., , ,Our De...
(Date:8/28/2008)...with person with dementia led to daytime tiredness...ug. 28 (HealthDay News) -- Older adults who live w...omeone with dementia have significantly worse slee..., The study compared 31 caregivers and 102 nonc...3 minutes less per night than non-caregivers and t...
(Date:8/28/2008)...f., Aug. 28 /PRNewswire-FirstCall/ -- ISTA Pharmac...t will present at the Thomas Weisel,Partners Healt...rsday,September 4, 2008 at the Four Seasons Hotel...tive Officer, Vicente Anido, Jr.,Ph.D., will prov...ical,progress. To access the live audio broadcast ...
Breaking Medicine News(10 mins):Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2Health News:Older Caregivers Prone to Worse Sleep Patterns 2
Plump Infants Getting Obese Later In Life In More Cases
...ound that there is no link whatsoever between brea...atins or lipid lowering drugs //to control the sam...October 24 issue of Archives of Internal Medicine,... article says that although some evidence has been...
... likely to invoke the compulsory licensing (CL) pr...tic drug //firms to produce and stockpile Swiss dr...combating the global threat against the most dread...ers the government to issue CL without receipt of ...
...ial lung disease (ILD) comprises a large, heteroge...rized by diffuse infiltrates, restrictive lung dis...mortality and morbidity. ILD presents enormous dia...ial diagnosis includes more than 100 conditions in...
Other Medicine News:Health News:A New Diagnostic Approach To Pediatric Interstitial Lung Disease 2
(Date:8/28/2008)... to collaborate on studies of immunosuppression ...diated immunity, COLUMBIA, Md., Aug. 28 /PRNewswi...n distributor, Sun Woo Biotech, is delighted to be...enter trial of the ImmuKnow assay,for cell-mediate...tutions,in the Republic of Korea," stated Brad Ste...
(Date:8/28/2008)... /- Intercell AG (VSE: ICLL) today,an...s initiated a Phase II,clinical trial of V710, an ...hylococcus aureus (S. aureus) infections. This ran...s to evaluate the safety and immunogenicity of,the...ey disease on,hemodialysis. This trial start follo...
(Date:8/27/2008)...in Parts of Bucks, Delaware, Montgomery,Philadelp...e-USNewswire/ -- After encouraging,results followi...tment of,Environmental Protection will continue it...st the mosquito-borne West Nile virus., Targeted ....m. and,midnight in portions of Bucks, Delaware, M...
(Date:8/27/2008)..., melphalan and prednisone arm demonstrated a, si... complete response -, CAMBRIDGE, Mass., Aug. 27 /...pany today announced the publication of results fr... trial in this week,s edition of the,New England J...nt survival,benefit and a 30 percent complete remi...
Breaking Medicine Technology:Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 2Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 3Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 2Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 3DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 1State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 2State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 3State of Arkansas Department of Human Services Division of Medical Services Selects U S Care Management for High Risk Obstetrics Health Management P 6752 4CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting 1885 1CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting 1885 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 1881 1Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 1881 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 1881 3Penn researchers find monkeys able to fend off AIDS like symptoms with enhanced HIV vaccine 1293 1Penn researchers find monkeys able to fend off AIDS like symptoms with enhanced HIV vaccine 1293 2
...ncer Conference, NORTH HOLLYWOOD, Calif., and CHIC...al Myeloma Foundation (IMF)-supporting research,an...eloma patients,families, researchers and physicia...e 3 multi- national clinical trial shows the,combi...obability of,survival by 41%. The follow-up study ...
...ity Support Development of Panzem(R),NCD as a Comb...ILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ --...company developing,therapeutics for the treatment ... presentation of results of a single-agent Phase 2...lioblastoma,multiforme (GBM). The data were presen...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 3Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 4
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: